Recruiting

Trial ID CA088-1000 | NCT06297226

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Summary

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.

Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and anti-B cell maturation antigen (BCMA) therapy], and at least 3 prior lines of therapy (LOT).
Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.
Participants must have measurable disease during screening.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Active or history of central nervous system involvement with MM.
Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.
Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.

Additional Information *

Study Arms

Experimental: BMS-986393

ASSIGNED INTERVENTION

Take the first step to see if you Match to a Clinical Trial – Check if you qualify

Check if you qualify

Answer some questions about Your health to see if you may match to this trial

Match to a Trial

If you are a match, click on the study to see the list of study site locations

Select a Study Site Location

Select a study site location that is convenient for you

Provide your contact details for the study site to connect with you.